Compare DRD & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRD | NEO |
|---|---|---|
| Founded | 1895 | 2001 |
| Country | South Africa | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Precision Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | 2002 | 2008 |
| Metric | DRD | NEO |
|---|---|---|
| Price | $24.02 | $16.51 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $21.85 |
| AVG Volume (30 Days) | 197.2K | ★ 2.0M |
| Earning Date | 10-23-2026 | 10-28-2026 |
| Dividend Yield | ★ 4.19% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.33 | $10.71 |
| Revenue Next Year | $18.47 | $9.96 |
| P/E Ratio | $15.32 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.47 | $7.07 |
| 52 Week High | $39.37 | $20.15 |
| Indicator | DRD | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 42.91 | 44.46 |
| Support Level | $23.19 | $15.57 |
| Resistance Level | $26.30 | $17.19 |
| Average True Range (ATR) | 0.65 | 0.97 |
| MACD | 0.07 | -0.06 |
| Stochastic Oscillator | 27.89 | 23.63 |
DRDGold Ltd is a South African gold mining company engaged in surface gold tailings retreatment, including exploration, extraction, processing, and smelting. Its reportable operating segments are: Ergo and FWGR. Ergo is a surface gold retreatment operation that treats old slime dams and sand dumps to the south of Johannesburg's central business district as well as the East and Central Rand goldfields, and FWGR is a surface gold retreatment operation that treats old slime dams in the West Rand goldfields. The Ergo segment derives the vast majority of the company's revenue.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.